Flu News and Research

RSS

Scientists to discuss the possibility of predicting evolution at scientific conference in Portugal

Is it possible to predict the evolution of the influenza virus? Or how rapidly bacteria evolve resistance to antibiotics? Or even how cancer cells spread inside a human being? These are some of the main topics of discussion that bring together renowned scientists from all over the world at the scientific conference "Forecasting evolution?" held at the Calouste Gulbenkian Foundation (FCG; Portugal) from 8th to 11th July.

3 Jul 2015

BiondVax Pharmaceuticals intends to close trading on NASDAQ market on July 10, 2015

BiondVax Pharmaceuticals Ltd. today announced that it will be closing trading on the NASDAQ market on Friday, July 10, 2015, in celebration of its recent initial public offering in the United States and the launch of its international investor relations program.

2 Jul 2015

Extreme heat and precipitation events linked to increased risk of Salmonella infections

Extreme heat and precipitation events, which are expected to increase in frequency and intensity due to climate change, are associated with increased risk of Salmonella infections, according to a study led by researchers from the University of Maryland School of Public Health.

2 Jul 2015

Researchers receive $1.35 million grant to study how influenza virus passes from birds to humans

An international research team led by Lukas Tamm of the University of Virginia School of Medicine will receive $1.35 million from the Human Frontier Science Program Organization to better understand how the influenza virus passes from birds to humans.

2 Jul 2015

National trial aims to reduce unnecessary use of antibiotics in post-acute and long-term care facilities

The University of Pittsburgh School of Medicine will be leading a $1.5 million national trial to examine methods to reduce unnecessary use of antibiotics in post-acute and long-term care (PA/LTC) facilities.

1 Jul 2015

BiondVax’s universal influenza vaccine meets safety and immunogenicity endpoints

BiondVax Pharmaceuticals Ltd. today announced positive preliminary results from its BVX-006 Phase II clinical trial of M-001, BiondVax's candidate for a universal influenza vaccine.

30 Jun 2015

Tris, Pfizer Consumer Healthcare sign agreement to market extended-release Robitussin for treatment of cough

Tris Pharma, Inc. today announced that it has entered into a license, supply, and distribution agreement with Pfizer Consumer Healthcare.

29 Jun 2015

UM SOM researcher uncovers new details about the body's response to flu virus

The flu virus can be lethal. But what is often just as dangerous is the body's own reaction to the invader. This immune response consists of an inflammatory attack, meant to kill the virus. But if it gets too aggressive, this counterattack can end up harming the body's own tissues, causing damage that can lead to death.

27 Jun 2015

UC Davis pediatricians describe challenges faced by children with asthma in California

Low flu vaccination rates, medication compliance and limited access to primary care providers have contributed to the high pediatric asthma rates in California, say UC Davis pediatricians Ulfat Shaikh and Robert Byrd, who have published an extensive study describing the challenges faced by children with asthma in California.

27 Jun 2015

Wistar Institute researchers identify specific mutations responsible for ineffectiveness of flu vaccines

Viruses like influenza have the ability to mutate over time, and given that the flu vaccines administered during the 2014-2015 season were largely ineffective at preventing the spread of the flu, it appears the virus that recently circulated had taken on mutations not accounted for when last year's vaccine was developed.

26 Jun 2015

BiondVax Pharmaceuticals declares closing of over-allotment option granted to underwriters

24 Jun 2015

Planning for first clinical trial of MERS-CoV vaccine candidate now underway

Researchers from Ludwig-Maximilians-Universitaet in Munich have demonstrated, in a preclinical setting, the protective effect of a candidate vaccine directed against the coronavirus that causes Middle East Respiratory Syndrome. Planning for the first clinical trial is now underway.

22 Jun 2015

Warming climate trend leads to smaller reductions in cold-related deaths

A study by researchers at Columbia University's Mailman School of Public Health debunks the assumption that global warming will lead to a decline in the number of deaths in winter. Findings by Professor Patrick Kinney, ScD, professor of Environmental Health Sciences and director of the School's Climate and Health Program, showed that a warming climate trend led to much smaller reductions in cold-related mortality than some experts have anticipated.

19 Jun 2015

Analysis of transportation data could help predict spread of flu epidemic across the U.S.

To predict how a seasonal influenza epidemic will spread across the United States, one should focus more on the mobility of people than on their geographic proximity, a new study suggests.

19 Jun 2015

Sequence of immunizations could be the promising route to HIV vaccine

The secret to preventing HIV infection lies within the human immune system, but the more-than-25-year search has so far failed to yield a vaccine capable of training the body to neutralize the ever-changing virus. New research from The Rockefeller University, and collaborating institutions, suggests no single shot will ever do the trick. Instead, the scientists find, a sequence of immunizations might be the most promising route to an HIV vaccine.

19 Jun 2015

FDA accepts BiondVax's IND for Multimeric-001 vaccine

BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases, today announced that its Investigational New Drug Application (IND) for its Multimeric-001 vaccine (M-001), has been accepted by the US Food and Drug Administration, and the Company was notified by its regulatory advisors that the 'study may proceed'.

17 Jun 2015

BiondVax invited to present at EDUFULVAC-NIAID workshop on immunoassay standardization for universal flu vaccines

BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases,today announced that it has been invited to present in a workshop organized by EDUFULVAC, (EDUcate inFLUenza VACcine) a corresponding European Consortium coordinated by the European Vaccine Initiative (Germany) and NIAID (the National Instituteof Allergy and Infectious Diseases, a National Institute of Health branch) in the United States.

16 Jun 2015

Novartis presents positive Phase III results of Farydak therapy at EHA

Novartis today presented results from a pivotal Phase III clinical trial exploratory subgroup analysis showing a 7.8-month improvement in median progression-free survival when using Farydak in combination with bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma who had received two or more prior regimens, including bortezomib and an immunomodulatory agent.

16 Jun 2015

Switching from Remicade to Inflectra benefits patients with rheumatic diseases

Hospira, Inc., a global leader in biosimilars, today announced the results of an independent clinical study, showing patients with rheumatic diseases experienced comparable clinical effectiveness and safety after switching from Remicade™ to Inflectra.

10 Jun 2015

Flynas adds Virus Guard disinfectant wipes to its in-flight hygiene to tackle MERS, Birdflu

Flynas, an award winning leading low cost airline of Saudi Arabia has set new standards to in-flight safety, by adding Virus Guard disinfectant wet wipes and sprays to its in-flight hygiene, to protect passengers from viruses such as MERS, Birdflu.

10 Jun 2015

Flu News and Research

Scientists to discuss the possibility of predicting evolution at scientific conference in Portugal

BiondVax Pharmaceuticals intends to close trading on NASDAQ market on July 10, 2015

Extreme heat and precipitation events linked to increased risk of Salmonella infections

Researchers receive $1.35 million grant to study how influenza virus passes from birds to humans

National trial aims to reduce unnecessary use of antibiotics in post-acute and long-term care facilities

BiondVax’s universal influenza vaccine meets safety and immunogenicity endpoints

Tris, Pfizer Consumer Healthcare sign agreement to market extended-release Robitussin for treatment of cough

UM SOM researcher uncovers new details about the body's response to flu virus

UC Davis pediatricians describe challenges faced by children with asthma in California

Wistar Institute researchers identify specific mutations responsible for ineffectiveness of flu vaccines

BiondVax Pharmaceuticals declares closing of over-allotment option granted to underwriters

Planning for first clinical trial of MERS-CoV vaccine candidate now underway

Warming climate trend leads to smaller reductions in cold-related deaths

Analysis of transportation data could help predict spread of flu epidemic across the U.S.

Sequence of immunizations could be the promising route to HIV vaccine

FDA accepts BiondVax's IND for Multimeric-001 vaccine

BiondVax invited to present at EDUFULVAC-NIAID workshop on immunoassay standardization for universal flu vaccines

Novartis presents positive Phase III results of Farydak therapy at EHA

Switching from Remicade to Inflectra benefits patients with rheumatic diseases

Flynas adds Virus Guard disinfectant wipes to its in-flight hygiene to tackle MERS, Birdflu

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News